Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS), and various types of cancer, is pleased to announce the upcoming presentation of complete Phase 1 clinical trial data for ANAVEX 2-73. The data will be revealed in a poster session at CNS Summit 2014 on November 14th. The poster was co-authored by Ole Voges and Ingo Weigmann of ABX-CRO, Norman Bitterlich of Medizin & Service GmbH, Christoph Schindler of Clinical Research Center, and Christopher U. Missling, President and CEO of Anavex.
The full Phase 1 findings will be presented as follows:
Title: A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects
Date: Friday, November 14, 2014
Time: 5:00 PM - 7:00 PM ET
Place: The Boca Raton Waldorf Astoria
501 East Camino Real, Boca Raton, FL 33432
Complete Phase 1 data will be reported by Anavex in a news release following the poster presentation.
With recent regulatory approval of ANAVEX 2-73 for a Phase 2a clinical trial, the Phase 1 data presentation will come at a key time for Anavex. ANAVEX 2-73, the Company’s lead proprietary compound, is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. The compound targets sigma-1 and muscarinic receptors, which have shown in preclinical studies to reduce the stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer’s.